Phase I/II study to evaluate the efficacy and safety of the combination treatment of melpharan, dexamethasone and bortezomib for relapsed or refractory systemic AL amyloidosis.
Phase of Trial: Phase I/II
Latest Information Update: 13 May 2016
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone; Melphalan
- Indications Amyloidosis
- Focus Therapeutic Use
- 29 Apr 2015 Status changed from recruiting to discontinued as reported by University Hospital Medical Information Network - Japan.
- 27 Oct 2011 New trial record